Brief: China NT Pharma Says Intention Of Konruns Pharmaceutical To Split Assets Of Beijing Kangchen Biotechnology
12/05/2025 11:31
May 12 (Reuters) - China NT Pharma Group Co Ltd 1011.HK: INTENTION OF KONRUNS PHARMACEUTICAL TO PROPOSE TO SPLIT ASSETS OF BEIJING KANGCHEN BIOTECHNOLOGY Further company coverage: 1011.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on China NT Pharma
See all newsBrief: China NT Pharma Receives Cietac Beijing Arbitration Award On July 20
Brief: China NT Pharma Establishes Formal Whistleblowing Policy
Brief: China NT Pharma Group Says Zhang Bozhi Resigns As CEO
Brief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY